PAINFUL MUSCLE SPASM: DIAGNOSIS AND PATHOGENETIC THERAPY
https://doi.org/10.21518/2079-701X-2017-5-24-27
Abstract
The article discusses the pathogenesis, diagnosis and treatment of myofascial pain. The analysis of the effectiveness of muscle relaxants in patients with myofascial pain syndrome is provided.
About the Author
O. V. VorobyovaRussian Federation
Sechenov First Moscow State Medical University of the Ministry of Health
References
1. Van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM; Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration. Spine, 2003 Sep 1, 28(17): 1978-92.
2. Rives PA, Douglass AB. Evaluation and treatment of low back pain in family practice. J Am Board Fam Pract, 2004, 17: S23-31.
3. Morikawa K, Oshita M, Yamazaki M, Ohara N, Mizutani F, Kato H, Ito Y, Kontani H, Koshiura R. Pharmacological studies of the new centrally acting muscle relaxant 4’-ethyl-2-methyl-3-pyrrolidinopropiophenone hydrochloride. Arzneimittelforschung, 1987 Mar, 37(3): 331-6.
4. Tekes K. Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant. Open Med Chem J, 2014, 8: 17–22.
5. Ono H, Fukuda H, Kudo Y. Mechanisms of depressant action of muscle relaxants on spinal reflexes: participation of membrane stabilizing action. J Pharmacobiodyn, 1984 Mar, 7(3): 171-6.
6. Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled doubleblind trial. Pain, 1996, 67(2-3): 417-425.
7. Kohne-Volland R. RGD: 53669/G. The study performed in Germany investigating the efficacy and tolerability of tolperisone on 5130 patients suffering in painful muscle spasm, 1999.
Review
For citations:
Vorobyova OV. PAINFUL MUSCLE SPASM: DIAGNOSIS AND PATHOGENETIC THERAPY. Meditsinskiy sovet = Medical Council. 2017;(5):24-27. (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-24-27